Cancer's Breakthrough Engine

Tuesday, December 19, at 1:00 p.m. ET / 10:00 a.m. PT

Since the development of Gleevec two decades ago, precision cancer medicines have become a driving force in biotech and a source of hope for cancer patients. What has worked best, and what hasn't? Join our panel of experts for a frank assessment.

Featured Speakers: 

• Axel Hoos, M.D., Ph.D., chief executive officer, Scorpion Therapeutics (sponsored speaker)
• Adam Feuerstein, senior writer, biotech, STAT (moderator)